Introduction
Anabolic steroids have been developed with the intent of using them for therapy; however, they have also been used illegally to improve physical performance in human sports and horseracing. Thus, the use of anabolic steroids is prohibited in athletes and racehorses. Dope testing laboratories have been requested to develop methods for the detection of possibly misused anabolic steroids. Anabolic steroids with the 17a-methyl,17b-hydroxy group were mainly developed for oral administration. Among them, fluoxymesterone (FOM, 11b,17b-dihydroxy-9a-fluoro17a-methyl-4-androsten-3-one) is prohibited by the World AntiDoping Code formulated by the International Olympic Committee (IOC) and the World Anti-Doping Agency (WADA). 1 There are some reports of urinary FOM metabolites in humans; Kammerer et al. proposed a metabolic pathway that involves 6b-hydroxylation, 4-ene reduction, 3-keto reduction, and 11-hydroxy oxidation of FOM. 2 Schänzer et al. identified FOM metabolites originating from 17-epimerization, 6b-hydroxylation, and 3-keto reduction, as well as 17,17-dimethyl-18-norandrost-13-ene, using synthesized reference compounds. [3] [4] [5] [6] On the other hand, Stanley et al. reported on FOM metabolites in horse urine; metabolites originating from C-6 or C-6, C-16 hydroxylation, and the 17-epimer were confirmed by LC/MS and GC/MS analyses. 7 To develop a suitable doping analysis of FOM in our laboratory, we investigated FOM metabolites in horse urine, and detected metabolites that have not been reported to date. In this study, based on GC/MS data of the metabolites excreted into horse urine after FOM administration, we synthesized the main metabolite and used it as a reference for identification and quantification. Using our analytical data, we considered the target metabolite for the doping tests of FOM used in horseracing.
Experimental

Steroids and chemicals
Authentic FOM was purchased from Kanto Kagaku Reagent Division (Tokyo, Japan). FOM used for oral administration was Halotestin ® (Pfizer Japan Inc., Tokyo, Japan). Nandrolone (NAD) was purchased from Steraloids (Newport, RI). 9a-Fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one was synthesized in our laboratory.
N-Methyl-Ntrimethylsilyl-trifluoroacetamide (MSTFA) was purchased from GL Sciences (Tokyo, Japan), and 1 mol/L hydrogen chloridemethanol solution was obtained from Kokusan Kagaku (Tokyo, Japan). p-Toluenesulfonic acid monohydrate (p-TsOH) was obtained from Wako Pure Chemical Industries. All reagents and solvents were of analytical or HPLC grade (purchased from Wako Pure Chemical Industries, Tokyo, Japan or Kanto Kagaku Reagent Division, Tokyo, Japan).
Synthesis of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one
FOM (1 g, 2.99 mmol) was dissolved in 100 mL of benzene and p-TsOH (1.1 g) was added. After the solution was refluxed for 30 min, the reaction product was extracted, dried, and recrystallized from ethyl acetate and hexane to yield 0.6 g of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one (yield 63%, mp 208 -210˚C Fluoxymesterone, an anabolic steroid with the 17a-methyl,17b-hydroxy group, has been developed as an oral formulation for therapeutic purposes. However, it is also used illegally in racehorses to enhance racing performance. In this study, we detected 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one by gas chromatography/mass spectrometry (GC/MS), which has not been reported as a fluoxymesterone metabolite so far in horse. It was synthesized for use as a reference standard, and characterized on the basis of 1 H NMR and 13 C NMR spectra, as well as GC/MS EI mass spectra of TMS derivatives. It was excreted as the main metabolite in horse urine, and its reference standard could be synthesized easily. Therefore, this metabolite could be a useful target for a doping test of fluoxymesterone in racehorses. 
Drug administration and sample collection
An aqueous suspension of Halotestin ® was administered to 3 gelding horses (13 -16 years old, 450 -600 kg) at a dose of 1.0 mg/kg through a nasogastric tube.
Urine samples were collected pre-administration and at 3, 6, 9, 12, 24, 48, and 72 h post-administration from each horse. All urine samples were stored at temperatures below -40˚C until analysis. All experimental procedures in this study were approved by Animal Care Committee of the Equine Research Institute, Japan Racing Association.
Sample preparation for structure elucidation of urinary metabolites
For the structure elucidation of metabolites in urine after FOM administration, extraction of unconjugated and conjugated metabolites was carried out and the extracts were divided into three fractions, namely, unconjugated steroid, glucuronide, and sulfate fractions. The sample preparation methods were the same as those used for 17a-methyltestosterone and mestanolone investigation. 8 Briefly, the urine sample was loaded onto a SepPak Plus C18 cartridge, and the unconjugated steroid fraction was eluted with diethyl ether. After collecting the unconjugated steroid fraction, the glucronide conjugates that remained in the column were eluted with ethyl acetate/methanol (4:1). They were subjected to hydrolysis with b-glucuronidase, and this solution was loaded onto another Sep-Pak Plus C18 cartridge. After the glucuronide fraction was eluted with diethyl ether, sulfate conjugates that remained in the column were eluted with ethyl acetate/methanol (4:1); they were subjected to methanolysis with an anhydrous hydrogen chloride-methanol solution, and the sulfate fraction was collected.
After trimethylsilyl (TMS) derivatization was performed in each sample fraction, the products of the reactions were analyzed by GC/MS.
Sample preparation for the quantification of urinary metabolites
To 1 mL of a urine sample was added 1 mg of NAD for use as an internal standard, followed by 0.5 mL of 1 mol/L NaOH and 7 mL of diethyl ether. After the mixture was shaken for 10 min and centrifuged at 1663 ¥ g for 10 min, the solvent layer was evaporated to dryness under nitrogen at temperatures below 40˚C. To the residue was added 0.5 mL of acetone, and the solution was evaporated again. The residue was dissolved in 100 mL of NH4I/dithioerythritol/MSTFA (2 mg/4 mg/1 mL) and reacted at 80˚C for 30 min; 1 mL of this solution was injected into GC/MS.
GC/MS analysis
GC/MS was performed on an HP 5973 mass selective detector (Agilent Technologies, Tokyo, Japan) connected to an HP 6890 Series GC. The fused-silica capillary columns used were DB-1, DB-5ms, and DB-17 (J & W Scientific, CA), each with 15 m ¥ 0.25 mm diameter and 0.25 mm film thickness. Helium was used as a carrier gas (1.0 mL/min), and the column oven temperature was programmed to increase from 150 to 210˚C at 20˚C/min, then to 300˚C at 10˚C/min, and maintained at 300˚C for 1 min. The injector temperature was set at 250˚C; the MS transfer line, at 275˚C; and ionization energy, at 70 eV. Structure elucidation of metabolites was carried out in the fullscan mode, and the capillary column used was DB-1. A structure determination of urinary metabolites with synthetic standards was carried out in the full-scan mode, and the capillary columns used were DB-1, DB-5ms, and DB-17. Quantification was carried out in the selected ion monitoring mode, and the capillary column used was DB-5ms.
NMR analysis
NMR spectra were recorded in methanol-d4, and chemical shifts were referenced relative to corresponding methanol (dH 3.30/dC 49.0) signals.
1 H-, 13 C-and all 2D NMR data were obtained using a Bruker Avance-400 instrument.
Results
Structure elucidation of urinary metabolites
GC/MS analysis indicated the presence of four metabolites in the unconjugated fraction, as shown in Fig. 1 . Their mass spectra are shown in Fig. 2 . After eliminating peaks that appeared in the chromatogram of the urine sample collected prior to FOM administration by comparison, four peaks corresponding to the metabolites were observed, and they were labeled F1 -F4 according to their retention times. Their mass spectra showed in common the loss of HF + (20 mass units) fragment ion from the molecular ion. Among them, the mass spectrum of F1 is the same as that of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one, which was reported as being one of the main metabolites in humans by Schänzer et al. 4 F2, on the other hand, had the same mass spectrum as FOM; however, their retention times were different. Thus, we presumed that F2 is a 17-epimer of FOM. F1 and F2 were reported to be produced via the 17b-sulfate of FOM in humans; therefore, we assumed that they were generated in the same manner as that in humans. 3 The mass spectra of both F3 and F4 showed a molecular ion at m/z 568, which is indicative of a tri-TMS derivative, and their GC/MS mass spectra have not been reported to date. The fragment ion at m/z 465 in the mass spectrum of F3 is due to the loss of CH2-O-Si(CH3)3 (103 mass units) from the molecular ion, and indicates the oxidation of the . On the basis of these data, F4 was tentatively identified as being the C-16 hydroxylated isomer of FOM. Besides the detection of metabolites in the unconjugated fraction, some urinary metabolites were detected in the glucuronide and sulfate fractions. They had fragment ions at m/z 231 and 218, and their molecular ions appeared at m/z 640, 642, 644, 728, and 730. Based on these results, the metabolites were presumed to be a C-16 hydroxylated isomer; a 3-keto or 4-ene reduced and C-16 hydroxylated isomer; a 3-keto and 4-ene reduced and C-16 hydroxylated isomer; a C-6,16 dihydroxylated isomer; a 3-keto or 4-ene reduced and C-6,16 dihydroxylated isomer; and a 3-keto and 4-ene reduced and C-6,16 dihydroxylated isomer, and they have been reported as FOM metabolites in horse or humans. [3] [4] [5] [6] [7] However, their peaks in the total ion chromatograms were very small compared with those of the metabolites of the unconjugated fraction, particularly F1.
Structure characterization of F1
From the results of a metabolite investigation, F1 was determined to be the main urinary metabolite in horse administered FOM. To confirm the structure of F1, 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one, which was elucidated as the structure of F1, was synthesized and compared with the urinary metabolite. A synthesis of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one from FOM was carried out by a general method. 11 It was very simple, as shown in Fig. 3 . The synthesized compound was characterized by analyzing the 1 H NMR and 13 C NMR spectra, as well as the GC/MS EI mass spectra of the TMS derivatives. F1 had the same retention times as the synthesized reference standard when they were subjected to GC/MS with three capillary columns having different stationary liquid phases (DB-1, DB-5ms, and DB-17). In addition, the obtained GC/MS mass spectrum data of F1 matched those of the synthesized compound. As far as we know, there is no report indicating that the 11-epimer is a metabolite of FOM in humans or horse. Thus, the structure of F1 was confirmed to be 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one.
Quantification of urinary metabolite F1
Since F1 was detected from the unconjugated fraction, it could be extracted without having to decompose the conjugates. Two standard curves prepared for the analysis of F1 over the concentration ranges of 5 -50 ng/mL and 50 -5000 ng/mL had correlation factors of 0.989 and 0.998, respectively, and the limit of quantification (LOQ) was 5 ng/mL. The recovery rates at concentrations of 5000, 50, and 5 ng/mL were 101, 100, and 101% (n = 7), respectively. The intra-day and inter-day precisions of the quantification method were assessed by analyzing urine samples spiked with the synthesized reference standard (5000, 50, 5 ng/mL). The precision was determined as the coefficient of variation (CV), and the inter-day precision was assessed by analyzing on three different days. The results of the intra-day precision were between 2.4 to 8.5% (n = 7), and those of the inter-day precision were between 2.4 to 9.1% (n = 7).
When the concentration of F1 exceeded 5000 ng/mL, the samples were diluted with a derivative reagent and analyzed again. The results are shown in Fig. 4 . The first urine sample was collected 30 min after FOM administration in horse B, and the next sample was obtained 6 h after administration. The first detection of F1 was from the urine sample collected 6 h after FOM administration in horse B. Since F1 was consistently detected from urine up to 12 h after FOM administration, the detection of metabolites other than F1 was investigated as well. However, those metabolites were hardly detected from urine 24 h after administration. In comparison with conventional injectable steroids, which tend to have a long excretion time, orally administered steroids, such as FOM, have short-term effects and a short excretion time. Therefore, we presumed that the urinary metabolites of FOM disappeared relatively early from horse urine.
Discussion
After FOM was administered to horses, urinary metabolites were investigated. As a result, we confirmed that 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one (F1) was excreted as the main metabolite in horse urine after FOM administration. We synthesized F1 and identified F1 in horse urine after FOM administration. As far as we know, there are no reports of F1 detection in horse urine after FOM administration, and F1 was reported to be produced via a 17b-sulfate of FOM in humans. 3 FOM metabolites in horse include not only F1, but also the 17-epimer and the 16-hydroxylate of FOM. However, F1 was detected as the main metabolite on the GC/MS total ion chromatogram. Although we acknowledge that comparing the data of detected metabolites and their synthesized reference standards is important in the doping test for racehorse, the acquisition of synthesized reference standards is sometimes difficult. However, the synthesis of F1 is very simple, as shown in Fig. 3 . From the quantification results, we found that although the detection period of F1 in horse urine after FOM administration is 12 -24 h, and metabolites other than F1 were also almost undetectable after that period in this study. Thus, the results suggest that F1 can be used as a target substance in the doping analysis of FOM in racehorses. Although studies have been conducted in humans, as far as we know, there are no detailed reports concerning the detection of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one in horse urine. This metabolite has potential use in the doping tests for FOM abuse in racehorses. Fig. 3 Synthesis of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one (F1) from fluoxymesterone. Fig. 4 Concentration of 9a-fluoro-17,17-dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one (F1) in horse urine.
